Home
Products
Learn
About
Pricing
Log In

What are you looking for?

Home
Pricing
Compare AU

Compare FSML vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

Firetrail Aust Small Companies Fund - Active ETF

ASX

Buy

Buy

Global X S&P Biotech ETF

ASX

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are FSML and CURE. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

FSML

CURE

Popularity

Low

Low

Pearlers invested

7

78

Median incremental investment

$855.00

$640.11

Median investment frequency

Weekly

Monthly

Median total investment

$2,300.09

$1,274.70

Average age group

> 35

> 35


Key Summary

FSML

CURE

Strategy

The fund's investment portfolio concentrates primarily on small cap equity. The Fund aims to outperform the S&P/ ASX Small Ordinaries Accumulation Index over the medium to long term

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

Firetrail Aust Small Companies Fund - Active ETF (100 %)

Natera Inc (2.73 %)

Alnylam Pharmaceuticals Inc (2.65 %)

Vertex Pharmaceuticals Inc (2.64 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0 %

0.45 %


Key Summary

FSML

CURE

Issuer

Firetraill

Global X

Tracking index

S&P/ASX Small Ordinaries Accumulation Index - AUD - Benchmark TR Gross

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0 %

0.45 %

Price

$1.69

$42.49

Size

N/A

$28.994 million

10Y return

N/A

N/A

Annual dividend/โ€Šdistribution yield (5Y)

- %

4.24 %

Market

ASX

ASX

First listed date

17/11/2024

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

FSML

CURE

Popularity

Low

Low

Pearlers invested

7

78

Median incremental investment

$855.00

$640.11

Median investment frequency

Weekly

Monthly

Median total investment

$2,300.09

$1,274.70

Average age group

> 35

> 35


Pros and Cons

FSML

CURE

Pros

  • Lower management fee

  • Higher price growth

  • Higher exposure to US market

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Lower distribution yield

  • Higher management fee

  • Lower price growth

FSML

CURE

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield